<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03974204</url>
  </required_header>
  <id_info>
    <org_study_id>Exo-LCR-1807</org_study_id>
    <secondary_id>2018-A02358-47</secondary_id>
    <nct_id>NCT03974204</nct_id>
  </id_info>
  <brief_title>Analyses of Exosomes in the Cerebrospinal Fluid for Breast Cancer Patients With Suspicion of Leptomeningeal Metastasis.</brief_title>
  <official_title>Benefit of Analyzing Exosomes in the Cerebrospinal Fluid During the Medical Care of Breast Cancer Patients With Suspicion of Leptomeningeal Metastasis.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Oscar Lambret</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Oscar Lambret</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, interventional, prospective study among breast cancer patients with a&#xD;
      suspicion of metastatic meningitis. The current study aims to assess the use of proteomic&#xD;
      profile issued from cerebrospinal fluid microvesicles for diagnosis of leptomeningeal&#xD;
      metastases.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of this study is to describe the association between the initial proteomic profile&#xD;
      issued from cerebrospinal fluid microvesicles and the initial cytological analysis of the&#xD;
      cerebrospinal fluid in breast cancer patients with a suspicion of metastatic meningitis.&#xD;
&#xD;
      Other objectives of the study include:&#xD;
&#xD;
        -  Describing the association between the initial proteomic profile and:&#xD;
&#xD;
             -  the histological types and hormonal receptors status of the breast cancer,&#xD;
&#xD;
             -  the likelihood of leptomeningeal metastasis according to the EANO-ESMO&#xD;
                classification (Lack of evidence / possible / probable / confirmed) ,&#xD;
&#xD;
             -  the likelihood of leptomeningeal metastasis according to the EANO-ESMO&#xD;
                classification, combined with histological type and hormonal receptors status.&#xD;
&#xD;
        -  Evaluate the prognostic value of the proteomic profiling for overall survival, according&#xD;
           to the EANO-ESMO classification and other known prognosis factors, in patients&#xD;
           classified &quot;possible&quot;, &quot;probable&quot; or &quot;confirmed&quot; leading to leptomeningeal metastases&#xD;
           specific treatment,&#xD;
&#xD;
        -  Evaluate the impact of the evolution of the proteomic profile a month after the start of&#xD;
           this treatment on the overall survival, in patients with leptomeningeal metastases&#xD;
           specific treatment,&#xD;
&#xD;
        -  Evaluate the association between the proteomic profile and the EANO-ESMO classification&#xD;
           at least 3 months after the initial EANO-ESMO classification,&#xD;
&#xD;
        -  Evaluate the evolution of the proteomic profile 3 months after the initial EANO-ESMO&#xD;
           classification, in patients initially classified &quot;lack of evidence&quot;, broadly and&#xD;
           according to the evolution of cytology, the administered treatments and to the EANO-ESMO&#xD;
           response if applicable,&#xD;
&#xD;
        -  Compare the proteomic profiles issued from cerebrospinal fluid and blood&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Modification of the care habits. We believe today that we are no longer able to carry out this&#xD;
    study as initially described.&#xD;
  </why_stopped>
  <start_date type="Anticipated">July 2019</start_date>
  <completion_date type="Anticipated">October 2023</completion_date>
  <primary_completion_date type="Anticipated">October 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proteomic profiles issued from cerebrospinal fluid at diagnosis</measure>
    <time_frame>Up to 1 week</time_frame>
    <description>Proteomic profile will be obtained by bioinformatic analysis of cerebrospinal fluid.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cytology of cerebrospinal fluid at diagnosis</measure>
    <time_frame>Up to 1 week</time_frame>
    <description>Results of cytological analysis of cerebrospinal fluid will be &quot;Positive&quot;, &quot;negative&quot;, &quot;equivocal&quot;.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proteomic profiles issued from cerebrospinal fluid</measure>
    <time_frame>Up to 3 months</time_frame>
    <description>Proteomic profile will be obtained by bioinformatic analysis of cerebrospinal fluid:&#xD;
1 month and 3 month after the start of a specific treatment of the leptomeningeal metastasis, if applicable,&#xD;
3 months after the initial diagnosis of leptomeningeal metastasis if the likehood of leptomeningeal metastasis is &quot;lack of evidence&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Histological subtype</measure>
    <time_frame>Before registration in study</time_frame>
    <description>Histological subtype will be subdivised as invasive ductal breast carcinoma, invasive lobular breast carcinoma, other brest carcinoma.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hormonal receptors status</measure>
    <time_frame>Before registration in study</time_frame>
    <description>Hormonal receptors status will be subdivised as:&#xD;
Positive hormonal receptors / Positive HER2&#xD;
Positive hormonal receptors / Negative HER2&#xD;
Negative hormonal receptors / Positive HER2&#xD;
Triple negative</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Likehood of leptomeningeal metastasis according to the EANO-ESMO classification.</measure>
    <time_frame>Up to 3 months after the intial diagnosis</time_frame>
    <description>EANO-ESMO classification is obtained by searching clinical symptoms, cancer cells in the cerebrospinal fluid (obtained by lumbar puncture), signs in RMI. The likehood of leptomeningeal metastasis is:&#xD;
Lack of evidence,&#xD;
Possible,&#xD;
Probable,&#xD;
Confirmed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Time from date of registration to date of death regardless of the cause, assessed up to 1 year</time_frame>
    <description>Overall survival is defined as time from date of registration to date of death regardless of the cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proteomic profiles issued from blood</measure>
    <time_frame>Up to 3 months after the intial diagnosis</time_frame>
    <description>Proteomic profile will be obtained by bioinformatic analysis of blood.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Leptomeningeal Metastasis</condition>
  <arm_group>
    <arm_group_label>Cerebrospinal fluid and Blood sample collection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Collection of cerebrospinal fluid and blood samples:&#xD;
At initial diagnostic assessment;&#xD;
1 month and 3 months after initial diagnostic assessment, for patients classified &quot;possible&quot;, &quot;probable&quot; or &quot;confirmed&quot; according to EANO-ESMO classification, leading to specific leptomeningeal metastase treatment;&#xD;
In case of symptoms leading to leptomeningeal metastase suspicion and at least 3 months after diagnostic assessment, for patients classified &quot;lack of evidence&quot; according to EANO-ESMO classification.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Cerebrospinal fluid and blood sample collection at the initial diagnostic assessment</intervention_name>
    <description>At the initial diagnostic assessment, 3mL of cerebrospinal fluid and 10 ml of blood sample will be collected in order to determine the proteomic profile. Cerebrospinal fluid will be collected during a lumbar puncture aiming to diagnose leptomeningeal metastases.</description>
    <arm_group_label>Cerebrospinal fluid and Blood sample collection</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Cerebrospinal fluid and blood sample collection if conclusions of initial diagnostic assessment are &quot;Lack of evidence&quot; according to EANO-ESMO classification</intervention_name>
    <description>3mL of cerebrospinal fluid and 10 ml of blood sample will be collected:&#xD;
When suspected metastatic meningitis symptoms arise and&#xD;
at least 3 months after the initial diagnostic assessment, In order to determine the proteomic profile. Cerebrospinal fluid will be collected during a lumbar puncture aiming to diagnose leptomeningeal metastases.</description>
    <arm_group_label>Cerebrospinal fluid and Blood sample collection</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Cerebrospinal fluid and blood sample collection if conclusions of initial diagnostic assessment are &quot;confirmed&quot;, &quot;probable&quot; or &quot;possible&quot;, leading to leptomeningeal metastase specific treatment</intervention_name>
    <description>3mL of cerebrospinal fluid and 10 ml of blood sample will be collected:&#xD;
1 month after the beginning of the specific treatment,&#xD;
3 months after the beginning of the specific treatment. Cerebrospinal fluid will be collected during a lumbar puncture aiming to assess treatment response or at intrathecal injection of treatment.</description>
    <arm_group_label>Cerebrospinal fluid and Blood sample collection</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient with histologically proven breast cancer&#xD;
&#xD;
          -  Patient with suspected metastatic leptomeningitis&#xD;
&#xD;
          -  Age ≥ 18 years&#xD;
&#xD;
          -  Patient covered by the French social security regime&#xD;
&#xD;
          -  Signed written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of cancer other than the one being treated&#xD;
&#xD;
          -  Contraindication to carrying out the lumbar puncture or cerebrospinal MRI&#xD;
&#xD;
          -  Pregnant or breastfeeding patient&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Emilie LE RHUN, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Oscar Lambret</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre Oscar Lambret</name>
      <address>
        <city>Lille</city>
        <state>Hauts-de- France</state>
        <zip>59020</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Régional Universitaire de Lille</name>
      <address>
        <city>Lille</city>
        <state>Hauts-de-France</state>
        <zip>59000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>May 31, 2019</study_first_submitted>
  <study_first_submitted_qc>June 3, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 4, 2019</study_first_posted>
  <last_update_submitted>October 5, 2021</last_update_submitted>
  <last_update_submitted_qc>October 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cerebrospinal fluid</keyword>
  <keyword>Proteomic profile</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Meningeal Carcinomatosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

